|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Genzyme Corporation (Nasdaq:GENZ), a leading biotechnology and medical device company. |
|---|---|
| Transferring Party | Bioenvision, Inc. (Nasdaq:BIVN), a developer of compounds and treatments for cancer and infectious diseases. |
| Sector | Biopharmaceuticals |
| Date | October 24, 2007 |
| Analysis Enhances Genzymes' oncology business by gaining exclusive, worldwide rights to clofarabine (Clolar), which was developed by both companies. Full ownership accelerates the development and commercialization of the therapy. Bioenvision also markets a treatment for post-menopausal breast cancer following relapse from initial hormone therapy, and has a pipeline to address unmet needs in autoimmune disease and infectious disease. Deal value -- $345m on limited sales currently. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |